Le développement des lignages hépatiques dans le foie normal et durant la régénération

Lemaigre, Frédéric P.

doi:10.1051/medsci/20122811014

Cited by 5 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De nombreuses recherches ont depuis mis en lumière l'importance d'un panel de miARN dans le développement embryonnaire du foie [35] (➜). La plupart sont dérégulés dans les pathologies hépatiques, telles que la maladie alcoolique du foie (MAF), les stéatopa-thies hépatiques non alcooliques et les états de fibrose, autant d'affections prédisposant au développement du CHC et, bien sûr, le CHC lui-même (Figure 3) ([9] pour revue).…”

Section: Expression Des Miarn Dans Les Pathologies Du Foieunclassified

See 1 more Smart Citation

Les microARN dans le cancer du foie

Gougelet

Colnot

2013

Med Sci (Paris)

View full text Add to dashboard Cite

Section: Expression Des Miarn Dans Les Pathologies Du Foieunclassified

“…C'est une cible du facteur de transcription HNF-4α (hepatocyte nuclear factor 4α), un acteur majeur de la différenciation des hépatocytes [35] (➜). MiR-122 est impliqué dans le métabolisme des lipides et du fer, et dans la synthèse de cholestérol ( [10,11] pour revue).…”

Section: Expression Des Miarn Dans Les Pathologies Du Foieunclassified

Les microARN dans le cancer du foie

Gougelet

Colnot

2013

Med Sci (Paris)

View full text Add to dashboard Cite

“…These cells have been estimated to account for between 0.01% and 1% of liver cells in neonates and, unlike foetal liver progenitor cells, they display no telomerase activity [14-16]. The intrahepatic stem cell niches are the canals of Hering in postnatal livers and are derived from ductal plates in foetal livers [17, 18]. We have also isolated foetal liver progenitor cells and demonstrated their ability to engraft in vivo [19], but limited access to these cells and their small numbers are major drawbacks.…”

Section: Introductionmentioning

confidence: 99%

Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy

Dianat¹,

Steichen²,

Vallier³

et al. 2013

CGT

View full text Add to dashboard Cite

The liver is affected by many types of diseases, including metabolic disorders and acute liver failure. Orthotopic liver transplantation (OLT) is currently the only effective treatment for life-threatening liver diseases but transplantation of allogeneic hepatocytes has now become an alternative as it is less invasive than OLT and can be performed repeatedly. However, this approach is hampered by the shortage of organ donors, and the problems related to the isolation of high quality adult hepatocytes, their cryopreservation and their absence of proliferation in culture. Liver is also a key organ to assess the pharmacokinetics and toxicology of xenobiotics and for drug discovery, but appropriate cell culture systems are lacking. All these problems have highlighted the need to explore other sources of cells such as stem cells that could be isolated, expanded to yield sufficiently large populations and then induced to differentiate into functional hepatocytes. The presence of a niche of “facultative” progenitor and stem cells in the normal liver has recently been confirmed but they display no telomerase activity. The recent discovery that human induced pluripotent stem cells can be generated from somatic cells has renewed hopes for regenerative medicine and in vitro disease modelling, as these cells are easily accessible. We review here the present progresses, limits and challenges for the generation of functional hepatocytes from human pluripotent stem cells in view of their potential use in regenerative medicine and drug discovery.

show abstract

Concise review: Clinical programs of stem cell therapies for liver and pancreas

et al. 2013

View full text Add to dashboard Cite

Regenerative medicine is transitioning into clinical programs utilizing stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands: they are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal-to-distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of fetal-liver-derived hepatic stem/progenitors transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100–150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes utilizing hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immune-modulatory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs’ effects are primarily via modulation of immune mechanisms.

show abstract

Le développement des lignages hépatiques dans le foie normal et durant la régénération

Cited by 5 publications

References 24 publications

Les microARN dans le cancer du foie

Les microARN dans le cancer du foie

Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy

Concise review: Clinical programs of stem cell therapies for liver and pancreas

Contact Info

Product

Resources

About